Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 116Carcinoma, Non-Small-Cell Lung 101Carcinoma, Renal Cell 67Colorectal Neoplasms 46Neoplasm Metastasis 40Squamous Cell Carcinoma of Head and Neck 38Carcinoma, Hepatocellular 38Neoplasms 35Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Hodgkin Disease 20Carcinoma, Transitional Cell 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 16Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Triple Negative Breast Neoplasms 13Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

darolutamide 2olaparib 1gedatolisib 1gallium 68 PSMA-11 1Surveys and Questionnaires 1Radiotherapy 1Prostate-Specific Antigen 1Pluvicto 1Nivolumab 1Lutetium-177 1Lutetium 1Cryotherapy 1Brachytherapy 1Androgen Antagonists 1Abiraterone Acetate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Diseases × Nivolumab × 1 year × Clear all
NCT03543189 2026-04-01

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
44 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡